PMID- 22786655 OWN - NLM STAT- MEDLINE DCOM- 20130107 LR - 20220310 IS - 1096-9896 (Electronic) IS - 0022-3417 (Linking) VI - 228 IP - 3 DP - 2012 Nov TI - Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFbeta2 in vascular abnormalization. PG - 378-90 LID - 10.1002/path.4072 [doi] AB - Glioblastoma are aggressive astrocytic brain tumours characterized by microvascular proliferation and an abnormal vasculature, giving rise to brain oedema and increased patient morbidity. Here, we have characterized the transcriptome of tumour-associated blood vessels and describe a gene signature clearly associated with pleomorphic, pathologically altered vessels in human glioblastoma (grade IV glioma). We identified 95 genes differentially expressed in glioblastoma vessels, while no significant differences in gene expression were detected between vessels in non-malignant brain and grade II glioma. Differential vascular expression of ANGPT2, CD93, ESM1, ELTD1, FILIP1L and TENC1 in human glioblastoma was validated by immunohistochemistry, using a tissue microarray. Through qPCR analysis of gene induction in primary endothelial cells, we provide evidence that increased VEGF-A and TGFbeta2 signalling in the tumour microenvironment is sufficient to invoke many of the changes in gene expression noted in glioblastoma vessels. Notably, we found an enrichment of Smad target genes within the distinct gene signature of glioblastoma vessels and a significant increase of Smad signalling complexes in the vasculature of human glioblastoma in situ. This indicates a key role of TGFbeta signalling in regulating vascular phenotype and suggests that, in addition to VEGF-A, TGFbeta2 may represent a new target for vascular normalization therapy. CI - Copyright (c) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. FAU - Dieterich, Lothar C AU - Dieterich LC AD - Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Sweden. FAU - Mellberg, Sofie AU - Mellberg S FAU - Langenkamp, Elise AU - Langenkamp E FAU - Zhang, Lei AU - Zhang L FAU - Zieba, Agata AU - Zieba A FAU - Salomaki, Henriikka AU - Salomaki H FAU - Teichert, Martin AU - Teichert M FAU - Huang, Hua AU - Huang H FAU - Edqvist, Per-Henrik AU - Edqvist PH FAU - Kraus, Theo AU - Kraus T FAU - Augustin, Hellmut G AU - Augustin HG FAU - Olofsson, Tommie AU - Olofsson T FAU - Larsson, Erik AU - Larsson E FAU - Soderberg, Ola AU - Soderberg O FAU - Molema, Grietje AU - Molema G FAU - Ponten, Fredrik AU - Ponten F FAU - Georgii-Hemming, Patrik AU - Georgii-Hemming P FAU - Alafuzoff, Irina AU - Alafuzoff I FAU - Dimberg, Anna AU - Dimberg A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120831 PL - England TA - J Pathol JT - The Journal of pathology JID - 0204634 RN - 0 (Transforming Growth Factor beta2) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Adult MH - Aged MH - Blood Vessels/*physiopathology MH - Brain Neoplasms/blood supply/pathology/*physiopathology MH - Case-Control Studies MH - Endothelium, Vascular/pathology/physiopathology MH - *Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic/physiology MH - Glioblastoma/blood supply/pathology/*physiopathology MH - Humans MH - Laser Capture Microdissection MH - Microarray Analysis MH - Middle Aged MH - Neoplasm Grading MH - Pericytes/pathology/physiology MH - Signal Transduction/physiology MH - Transforming Growth Factor beta2/genetics/*physiology MH - Vascular Endothelial Growth Factor A/genetics/*physiology EDAT- 2012/07/13 06:00 MHDA- 2013/01/08 06:00 CRDT- 2012/07/13 06:00 PHST- 2011/06/11 00:00 [received] PHST- 2012/07/03 00:00 [revised] PHST- 2012/07/04 00:00 [accepted] PHST- 2012/07/13 06:00 [entrez] PHST- 2012/07/13 06:00 [pubmed] PHST- 2013/01/08 06:00 [medline] AID - 10.1002/path.4072 [doi] PST - ppublish SO - J Pathol. 2012 Nov;228(3):378-90. doi: 10.1002/path.4072. Epub 2012 Aug 31.